British pharma major AstraZeneca (LSE: AZN) has presented new
data from the INFORM and COVIDRIVE real-world studies at the
annual meeting of the European Society of Clinical Microbiology
and Infectious Diseases (ECCMID).
The results show the significant burden of COVID-19 on
immunocompromised patients, compared to the general population.
Data from INFORM show that, despite receiving at least four
vaccinations, many such individuals remain poorly protected…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.